Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

被引:1
|
作者
Casey, Maximilian [1 ]
Pannu, Sonia [2 ]
Bajwa, Saffia [1 ]
Duarte-Garcia, Ali [3 ]
Putman, Michael [1 ]
机构
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Univ Sch Milwaukee, River Hills, WI USA
[3] Mayo Clin, Rochester, MN USA
关键词
DEMYELINIZING NEUROLOGICAL DISEASE; FACTOR-ALPHA THERAPY; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; DEMYELINATING DISEASE; ANTAGONISTS; INFLIXIMAB; INHIBITORS; DATABASE; EVENTS;
D O I
10.1002/acr.25340
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveNeuroinflammatory adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to date have compared the real-world risk of TNFs with other new users of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). The objective of this study is to describe the risk of neuroinflammatory disease after initiation b/tsDMARDs.MethodsThis new user comparative effectiveness cohort study used a large US-based electronic health records database to describe the unadjusted incidence of neuroinflammatory adverse events over a 3-year period. The cohort included patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis initiating treatment with a TNF inhibitor (n = 93,661) or other b/tsDMARD (n = 38,354).ResultsAmong 132,015 patients included in the analysis, the most common first biologic agent was a TNF inhibitor; the unadjusted incidence of neuroinflammatory events was numerically lower among new users of TNF inhibitors (incidence 1.34 per 1,000 patient-years) as compared with the combined non-TNF group (1.69 per 1,000 patient-years). There was no significant association between TNF exposure and neuroinflammatory events as compared with the combined non-TNF b/tsDMARDs overall (hazard ratio 1.01; 95% confidence interval 0.75-1.36) and within each disease group.ConclusionThe overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared with new users of other b/tsDMARDs. Meta-analyses of randomized trials should be conducted to corroborate these findings, which may be affected by channeling bias.
引用
收藏
页码:1203 / 1209
页数:7
相关论文
共 50 条
  • [21] Disease-Modifying Antirheumatic Drugs
    Brasington, Richard
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 2009, 34A (02): : 347 - 348
  • [22] Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review
    Kingsley, Gabrielle H.
    Scott, David L.
    PSORIASIS-TARGETS AND THERAPY, 2015, 5 : 71 - 81
  • [23] Disease-modifying antirheumatic drugs
    Lambert, David G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2009, 10 (01): : 35 - 37
  • [24] Disease-modifying antirheumatic drugs
    Slack, S
    Furst, DE
    DRUGS OF TODAY, 1996, 32 (06) : 463 - 476
  • [25] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    SMITH, MD
    AHERN, MJ
    MEDICAL JOURNAL OF AUSTRALIA, 1992, 157 (11-12) : 797 - 801
  • [26] Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients
    Xie, Fenglong
    Yun, Huifeng
    Levitan, Emily B.
    Muntner, Paul
    Curtis, Jeffrey R.
    ARTHRITIS CARE & RESEARCH, 2019, 71 (08) : 1004 - 1018
  • [27] Decision Aid-Led Tapering of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Qualitative Study
    Lee, Jungyeon
    Barber, Claire E. H.
    Jung, Michelle
    Kaminska, Elzbieta
    Bansback, Nick
    Richards, Dawn
    Proulx, Laurie
    Rebutoc, Ann
    Hazlewood, Glen S.
    JOURNAL OF RHEUMATOLOGY, 2024, 51 (12) : 1077 - 1083
  • [28] Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
    Hosseini, Roya
    Brown, Lawrence
    Fleming, Marc
    Rodriguez-Monguio, Rosa
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2161 - 2162
  • [29] Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
    Conway, Richard
    Corcoran, Luke
    Nikiphorou, Elena
    INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (05) : 92 - 100
  • [30] Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
    Fletcher, Ashley
    Lassere, Marissa
    March, Lyn
    Hill, Catherine
    Barrett, Claire
    Carroll, Graeme
    Buchbinder, Rachelle
    RHEUMATOLOGY, 2022, 61 (10) : 3939 - 3951